We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Athersys Inc | NASDAQ:ATHX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.1018 | 0.101 | 0.104 | 0 | 01:00:00 |
Athersys, Inc. (“Athersys”) (NASDAQ: ATHX) announced today that its partner in Japan, HEALIOS K.K. (“Healios”), exercised in full its warrant to purchase shares of Athersys common stock. Healios purchased 4,000,000 shares at a price of $1.76 per share in accordance with the terms of the warrant, representing an additional investment of $7,040,000 in Athersys.
This warrant was issued to Healios in March 2018 as part of an expansion of the collaboration between the companies. This expansion agreement set the warrant exercise price at 110% of the average price per share over the ten days preceding exercise, or $1.76 per share so long as the reference price remained below this floor.
Healios previously purchased 12,000,000 shares of Athersys common stock and now owns approximately 9.4% of the current outstanding shares of Athersys. There are no other warrants outstanding.
About Athersys
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200330005138/en/
Ivor Macleod Chief Financial Officer Tel: (216) 431-9900 ir@athersys.com
Karen Hunady Director of Corporate Communications & Investor Relations Tel: (216) 431-9900 khunady@athersys.com
David Schull Russo Partners, LLC Tel: (212) 845-4271 or (858) 717-2310 David.schull@russopartnersllc.com
1 Year Athersys Chart |
1 Month Athersys Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions